F1_M3

NTP Study Number:	C20209
Lock Date:	08/31/2011
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	3.0.2.1_001
PWG Approval Date:	NONE

HISTORICAL CONTROL STUDIES
From June 2013 report

SAME ROUTE
99031-04 -- Ginkgo biloba extract (GAVAGE CORN OIL)
20006-04 -- Indole-3-carbinol (GAVAGE CORN OIL)
20007-06 -- Kava kava extract (GAVAGE CORN OIL)
20107-04 -- N,N-Dimethyl-p-toluidine (GAVAGE CORN OIL)
20320-04 -- Tetrabromobisphenol A (GAVAGE CORN OIL)

ALL ROUTES
99037-06 -- alpha/beta Thujone mixture (GAVAGE METHYLCELLULOSE)
20011-06 -- 1-Bromopropane (INHALATION AIR)
60311-06 -- Cobalt (INHALATION AIR)
99017-06 -- Diethylamine (INHALATION AIR)
99031-04 -- Ginkgo biloba extract (GAVAGE CORN OIL)
20005-06 -- Ginseng (GAVAGE WATER)
20203-04 -- Green tea extract (GAVAGE WATER)
20006-04 -- Indole-3-carbinol (GAVAGE CORN OIL)
20007-06 -- Kava kava extract (GAVAGE CORN OIL)
20515-04 -- Metal working fluids (CIMSTAR 3800) (INHALATION AIR)
95003-06 -- Methyl trans-styryl ketone (SKIN ETHANOL)
20107-04 -- N,N-Dimethyl-p-toluidine (GAVAGE CORN OIL)
20009-04 -- beta-Picoline (ORAL WATER)
99032-04 -- Pyrogallol (SKIN ETHANOL)
20320-04 -- Tetrabromobisphenol A (GAVAGE CORN OIL)
93025-06 -- Tetralin (INHALATION AIR)
88133-08 -- Trimethylolpropane triacrylate (SKIN ACETONE)
20303-06 -- Vinylidene chloride (INHALATION AIR)
96014-06 -- Water disinfection byproducts (Bromodichloroacetic acid) (ORAL WATER)

FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED. IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.

Adrenal Cortex
Islets, Pancreatic
Kidney
Liver
Lung
Ovary
Pituitary Gland
Testes
Thyroid Gland

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF PENTABROMODIPHENYL OXIDE (TECHNICAL) (DE 71)

MALE MICE

Organ	Morphology
Harderian Gland	Adenoma
	Carcinoma or Adenoma
Intestine Small: Site Unspecified	Carcinoma or Adenoma
Liver	Hepatoblastoma
	Hepatocellular Adenoma
	Hepatocellular Carcinoma
	Hepatocellular Carcinoma or Hepatoblastoma
	Hepatocellular Carcinoma or Hepatocellular Adenoma
	Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung	Alveolar/Bronchiolar Adenoma
	Alveolar/Bronchiolar Carcinoma
	Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
All Organs	Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type
	Benign Tumors
	Malignant Tumors
	Malignant and Benign Tumors

FEMALE MICE

Organ	Morphology
Harderian Gland	Adenoma
	Carcinoma or Adenoma
Liver	Hepatocellular Adenoma
	Hepatocellular Carcinoma
	Hepatocellular Carcinoma or Hepatoblastoma
	Hepatocellular Carcinoma or Hepatocellular Adenoma
	Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung	Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
Pituitary Gland: Pars Distalis or Unspecified Site	Adenoma
Skin	Mast Cell Tumor Benign
Stomach, Forestomach	Squamous Cell Papilloma
Uterus	Polyp Stromal
All Organs	Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF PENTABROMODIPHENYL OXIDE (TECHNICAL) (DE 71)

Benign Tumors
Malignant Tumors
Malignant and Benign Tumors

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Adrenal Cortex Adenoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	1/49 (2%)	0/48 (0%)
POLY-3 RATE (b)	0/40.02	1/43.38	1/43.04	0/17.62
POLY-3 PERCENT (g)	0%	2.3%	2.3%	0%
TERMINAL (d)	0/29 (0%)	1/33 (3%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---
HC TUMORS SAME ROUTE	5/250 (2%)			
HC TUMORS ALL ROUTES	57/945 (6%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Harderian Gland Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	6/50 (12%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	5/40.20	6/43.38	3/44.65	0/18.16
POLY-3 PERCENT (g)	12.4%	13.8%	6.7%	0%
TERMINAL (d)	4/29 (14%)	6/33 (18%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	684	729 (T)	618	---
HC TUMORS SAME ROUTE	33/250 (13%)			
HC TUMORS ALL ROUTES	119/950 (13%)			
STATISTICAL TESTS				
POLY 3	P=0.078N	P=0.554	P=0.300N	P=0.175N
POLY 1.5	P=0.041N*	P=0.539	P=0.319N	P=0.081N
POLY 6	P=0.132N	P=0.571	P=0.275N	P=0.402N
COCH-ARM / FISHERS	P=0.013N*	P=0.500	P=0.357N	P=0.028N*
MAX-ISO-POLY-3	P=0.128N	P=0.426	P=0.197N	P=0.142N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)
CURR VS HC SAME RTE	P=0.657			
CURR VS HC ALL RTES	P=0.755			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Harderian Gland **Carcinoma or Adenoma**				
TUMOR RATES	#	#	#	#
OVERALL (a)	6/50 (12%)	6/50 (12%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	6/40.20	6/43.38	3/44.65	0/18.16
POLY-3 PERCENT (g)	14.9%	13.8%	6.7%	0%
TERMINAL (d)	5/29 (17%)	6/33 (18%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	684	729 (T)	618	---
HC TUMORS SAME ROUTE	38/250 (15%)			
HC TUMORS ALL ROUTES	153/950 (16%)			
STATISTICAL TESTS				
POLY 3	P=0.057N	P=0.567N	P=0.192N	P=0.131N
POLY 1.5	P=0.030N*	P=0.582N	P=0.209N	P=0.051N
POLY 6	P=0.093N	P=0.550N	P=0.170N	P=0.363N
COCH-ARM / FISHERS	P=0.009N**	P=0.620N	P=0.243N	P=0.013N*
MAX-ISO-POLY-3	P=0.093N	P=0.444N	P=0.122N	P=0.117N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)
CURR VS HC SAME RTE	P=0.700			
CURR VS HC ALL RTES	P=0.607			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Intestine Small: Site Unspecified Carcinoma or Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	2/19.70
POLY-3 PERCENT (g)	0%	0%	0%	10.2%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	442
HC TUMORS SAME ROUTE	9/250 (4%)			
HC TUMORS ALL ROUTES	31/950 (3%)			
STATISTICAL TESTS				
POLY 3	P=0.025*	(e)	(e)	P=0.123
POLY 1.5	P=0.027*	(e)	(e)	P=0.168
POLY 6	P=0.118	(e)	(e)	P=0.081
COCH-ARM / FISHERS	P=0.041*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.035*	(e)	(e)	P=0.072
HISTCONT SAME RTE	P=0.344	(e)	(e)	P=0.279
HISTCONT ALL RTES	P=0.294	(e)	(e)	P=0.203
CURR VS HC SAME RTE	P=0.204			
CURR VS HC ALL RTES	P=0.262			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Islets, Pancreatic Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	2.5%	0%	0%	0%
TERMINAL (d)	1/29 (3%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	---	---
HC TUMORS SAME ROUTE	3/250 (1%)			
HC TUMORS ALL ROUTES	21/945 (2%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Kidney: Renal Tubule Carcinoma or Adenoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	2/43.94	1/43.21	0/18.16
POLY-3 PERCENT (g)	0%	4.6%	2.3%	0%
TERMINAL (d)	0/29 (0%)	1/33 (3%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	557	684	---
HC TUMORS SAME ROUTE	2/250 (1%)			
HC TUMORS ALL ROUTES	11/944 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.496N	P=0.258	P=0.515	(e)
POLY 1.5	P=0.420N	P=0.252	P=0.509	(e)
POLY 6	P=0.684N	P=0.267	P=0.524	(e)
COCH-ARM / FISHERS	P=0.339N	P=0.247	P=0.495	(e)
MAX-ISO-POLY-3	P=0.533	P=0.096	P=0.178	(e)
HISTCONT SAME RTE	P=0.546	P=0.075	P=1.000	(e)
HISTCONT ALL RTES	P=0.639	P=0.103	P=1.000	(e)
CURR VS HC SAME RTE	P=0.541			
CURR VS HC ALL RTES	P=0.569			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Liver **Hepatoblastoma**				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	1/50 (2%)	16/50 (32%)	5/50 (10%)
POLY-3 RATE (b)	1/40.02	1/43.38	16/45.77	5/21.33
POLY-3 PERCENT (g)	2.5%	2.3%	35%	23.4%
TERMINAL (d)	1/29 (3%)	1/33 (3%)	9/31 (29%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	453	477
HC TUMORS SAME ROUTE	9/250 (4%)			
HC TUMORS ALL ROUTES	40/949 (4%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.743N	P<0.001**	P=0.020*
POLY 1.5	P=0.009**	P=0.748N	P<0.001**	P=0.044*
POLY 6	P<0.001**	P=0.736N	P<0.001**	P=0.006**
COCH-ARM / FISHERS	P=0.157	P=0.753N	P<0.001**	P=0.102
MAX-ISO-POLY-3	P<0.001**	P=0.477N	P<0.001**	P=0.023*
HISTCONT SAME RTE	P=0.020*	P=1.000	P=0.002**	P=0.042*
HISTCONT ALL RTES	P<0.001**	P=1.000	P<0.001**	P=0.014*
CURR VS HC SAME RTE	P=0.626			
CURR VS HC ALL RTES	P=0.517			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Liver **Hepatocellular Adenoma**				
TUMOR RATES				
OVERALL (a)	23/50 (46%)	35/50 (70%)	49/50 (98%)	40/50 (80%)
POLY-3 RATE (b)	23/43.26	35/48.01	49/49.59	40/42.77
POLY-3 PERCENT (g)	53.2%	72.9%	98.8%	93.5%
TERMINAL (d)	15/29 (52%)	25/33 (76%)	31/31 (100%)	0/0 (0%)
FIRST INCIDENCE	491	428	431	451
HC TUMORS SAME ROUTE	145/250 (58%)			
HC TUMORS ALL ROUTES	594/949 (63%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.034*	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.025*	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.049*	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.005**	P=0.013*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.026*	P<0.001**	P<0.001**
HISTCONT SAME RTE	P=0.012*	P=0.039*	P<0.001**	P=0.003**
HISTCONT ALL RTES	P=0.002**	P=0.282	P<0.001**	P=0.002**
CURR VS HC SAME RTE	P=0.119			
CURR VS HC ALL RTES	P=0.042*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Liver **Hepatocellular Carcinoma**				
TUMOR RATES				
OVERALL (a)	18/50 (36%)	15/50 (30%)	30/50 (60%)	45/50 (90%)
POLY-3 RATE (b)	18/44.25	15/45.53	30/46.03	45/46.05
POLY-3 PERCENT (g)	40.7%	33%	65.2%	97.7%
TERMINAL (d)	8/29 (28%)	9/33 (27%)	21/31 (68%)	0/0 (0%)
FIRST INCIDENCE	491	540	453	451
HC TUMORS SAME ROUTE	87/250 (35%)			
HC TUMORS ALL ROUTES	348/949 (37%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.293N	P=0.013*	P<0.001**
POLY 1.5	P<0.001**	P=0.296N	P=0.014*	P<0.001**
POLY 6	P<0.001**	P=0.293N	P=0.013*	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.335N	P=0.014*	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.226N	P=0.008**	P<0.001**
HISTCONT SAME RTE	P=0.002**	P=1.000	P=0.017*	P<0.001**
HISTCONT ALL RTES	P<0.001**	P=1.000	P=0.005**	P<0.001**
CURR VS HC SAME RTE	P=0.790			
CURR VS HC ALL RTES	P=0.905			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Liver				
Hepatocellular Carcinoma or Hepatoblastoma				
TUMOR RATES				
OVERALL (a)	18/50 (36%)	15/50 (30%)	36/50 (72%)	45/50 (90%)
POLY-3 RATE (b)	18/44.25	15/45.53	36/46.87	45/46.05
POLY-3 PERCENT (g)	40.7%	33%	76.8%	97.7%
TERMINAL (d)	8/29 (28%)	9/33 (27%)	25/31 (81%)	0/0 (0%)
FIRST INCIDENCE	491	540	453	451
HC TUMORS SAME ROUTE	93/250 (37%)			
HC TUMORS ALL ROUTES	371/949 (39%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.293N	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.296N	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.293N	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.335N	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.226N	P<0.001**	P<0.001**
HISTCONT SAME RTE	P=0.002**	P=1.000	P=0.006**	P=0.002**
HISTCONT ALL RTES	P<0.001**	P=1.000	P<0.001**	P<0.001**
CURR VS HC SAME RTE	P=0.972			
CURR VS HC ALL RTES	P=0.839			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Hepatocellular Carcinoma or Hepatocellular Adenoma				
TUMOR RATES				
OVERALL (a)	31/50 (62%)	40/50 (80%)	49/50 (98%)	47/50 (94%)
POLY-3 RATE (b)	31/45.54	40/49.01	49/49.59	47/47.22
POLY-3 PERCENT (g)	68.1%	81.6%	98.8%	99.5%
TERMINAL (d)	18/29 (62%)	26/33 (79%)	31/31 (100%)	0/0 (0%)
FIRST INCIDENCE	491	428	431	451
HC TUMORS SAME ROUTE	189/250 (76%)			
HC TUMORS ALL ROUTES	742/949 (78%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.092	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.074	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.117	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.038*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.064	P<0.001**	P<0.001**
HISTCONT SAME RTE	P=0.008**	P=0.478	P=0.003**	P=0.003**
HISTCONT ALL RTES	P=0.004**	P=1.000	P=0.003**	P=0.003**
CURR VS HC SAME RTE	P=0.044*			
CURR VS HC ALL RTES	P=0.021*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma				
TUMOR RATES				
OVERALL (a)	31/50 (62%)	40/50 (80%)	49/50 (98%)	47/50 (94%)
POLY-3 RATE (b)	31/45.54	40/49.01	49/49.59	47/47.22
POLY-3 PERCENT (g)	68.1%	81.6%	98.8%	99.5%
TERMINAL (d)	18/29 (62%)	26/33 (79%)	31/31 (100%)	0/0 (0%)
FIRST INCIDENCE	491	428	431	451
HC TUMORS SAME ROUTE	190/250 (76%)			
HC TUMORS ALL ROUTES	746/949 (79%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.092	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.074	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.117	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.038*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.064	P<0.001**	P<0.001**
HISTCONT SAME RTE	P=0.008**	P=1.000	P=0.003**	P=0.003**
HISTCONT ALL RTES	P=0.005**	P=1.000	P=0.003**	P=0.004**
CURR VS HC SAME RTE	P=0.035*			
CURR VS HC ALL RTES	P=0.017*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Lung **Alveolar/Bronchiolar Adenoma**				
TUMOR RATES				
OVERALL (a)	5/50 (10%)	6/50 (12%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	5/40.35	6/43.94	3/43.98	1/18.74
POLY-3 PERCENT (g)	12.4%	13.7%	6.8%	5.3%
TERMINAL (d)	4/29 (14%)	5/33 (15%)	3/31 (10%)	0/0 (0%)
FIRST INCIDENCE	639	557	729 (T)	543
HC TUMORS SAME ROUTE	38/250 (15%)			
HC TUMORS ALL ROUTES	145/950 (15%)			
STATISTICAL TESTS				
POLY 3	P=0.177N	P=0.560	P=0.309N	P=0.371N
POLY 1.5	P=0.113N	P=0.542	P=0.324N	P=0.216N
POLY 6	P=0.238N	P=0.580	P=0.291N	P=0.627N
COCH-ARM / FISHERS	P=0.044N*	P=0.500	P=0.357N	P=0.102N
MAX-ISO-POLY-3	P=0.292N	P=0.433	P=0.203N	P=0.283N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)
CURR VS HC SAME RTE	P=0.429			
CURR VS HC ALL RTES	P=0.429			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung **Alveolar/Bronchiolar Carcinoma**				
TUMOR RATES				
OVERALL (a)	5/50 (10%)	6/50 (12%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	5/40.55	6/43.38	1/43.98	0/18.16
POLY-3 PERCENT (g)	12.3%	13.8%	2.3%	0%
TERMINAL (d)	4/29 (14%)	6/33 (18%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	568	729 (T)	729 (T)	---
HC TUMORS SAME ROUTE	23/250 (9%)			
HC TUMORS ALL ROUTES	132/950 (14%)			
STATISTICAL TESTS				
POLY 3	P=0.029N*	P=0.548	P=0.083N	P=0.177N
POLY 1.5	P=0.021N*	P=0.535	P=0.089N	P=0.082N
POLY 6	P=0.028N*	P=0.562	P=0.076N	P=0.405N
COCH-ARM / FISHERS	P=0.010N**	P=0.500	P=0.102N	P=0.028N*
MAX-ISO-POLY-3	P=0.047N*	P=0.420	P=0.040N*	P=0.144N
HISTCONT SAME RTE	P=1.000	P=0.386	P=1.000	P=1.000
HISTCONT ALL RTES	(h)	(h)	(h)	(h)
CURR VS HC SAME RTE	P=0.787			
CURR VS HC ALL RTES	P=0.575			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Lung				
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma				
TUMOR RATES				
OVERALL (a)	10/50 (20%)	12/50 (24%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	10/40.88	12/43.94	4/43.98	1/18.74
POLY-3 PERCENT (g)	24.5%	27.3%	9.1%	5.3%
TERMINAL (d)	8/29 (28%)	11/33 (33%)	4/31 (13%)	0/0 (0%)
FIRST INCIDENCE	568	557	729 (T)	543
HC TUMORS SAME ROUTE	59/250 (24%)			
HC TUMORS ALL ROUTES	263/950 (28%)			
STATISTICAL TESTS				
POLY 3	P=0.013N*	P=0.480	P=0.051N	P=0.103N
POLY 1.5	P=0.005N**	P=0.460	P=0.057N	P=0.025N*
POLY 6	P=0.017N*	P=0.501	P=0.044N*	P=0.402N
COCH-ARM / FISHERS	P<0.001N**	P=0.405	P=0.074N	P=0.004N**
MAX-ISO-POLY-3	P=0.021N*	P=0.384	P=0.031N*	P=0.107N
HISTCONT SAME RTE	P=1.000	P=1.000	P=1.000	P=1.000
HISTCONT ALL RTES	(h)	(h)	(h)	(h)
CURR VS HC SAME RTE	P=0.742			
CURR VS HC ALL RTES	P=0.384			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

			Males	
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Pituitary Gland: Pars Distalis or Unspecified Site Adenoma				
TUMOR RATES				
OVERALL (a)	0/47 (0%)	1/43 (2%)	0/43 (0%)	0/44 (0%)
POLY-3 RATE (b)	0/37.99	1/37.41	0/38.02	0/15.95
POLY-3 PERCENT (g)	0%	2.7%	0%	0%
TERMINAL (d)	0/28 (0%)	1/29 (3%)	0/27 (0%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
HC TUMORS SAME ROUTE	0/248 (0%)			
HC TUMORS ALL ROUTES	3/933 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Pituitary Gland: Pars Intermedia Adenoma				
TUMOR RATES				
OVERALL (a)	0/47 (0%)	0/43 (0%)	0/43 (0%)	0/44 (0%)
POLY-3 RATE (b)	0/37.99	0/37.41	0/38.02	0/15.95
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/28 (0%)	0/29 (0%)	0/27 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	1/248 (0%)			
HC TUMORS ALL ROUTES	2/933 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Skeletal Muscle Rhabdomyosarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	1/950 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Skin				
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	2/250 (1%)			
HC TUMORS ALL ROUTES	11/950 (1%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Skin				
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	2/250 (1%)			
HC TUMORS ALL ROUTES	11/950 (1%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Skin **Lipoma**				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/40.96	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	4.9%	0%	0%	0%
TERMINAL (d)	1/29 (3%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	298	---	---	---
HC TUMORS SAME ROUTE	1/250 (0%)			
HC TUMORS ALL ROUTES	2/950 (0%)			
STATISTICAL TESTS				
POLY 3	P=0.276N	P=0.224N	P=0.221N	P=0.439N
POLY 1.5	P=0.296N	P=0.228N	P=0.227N	P=0.337N
POLY 6	P=0.305N	P=0.219N	P=0.213N	P=0.585N
COCH-ARM / FISHERS	P=0.289N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.303N	P=0.075N	P=0.075N	P=0.262N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)
CURR VS HC SAME RTE	P=0.045*			
CURR VS HC ALL RTES	P<0.001**			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Skin				
Mast Cell Tumor Benign				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	1/44.16	0/18.16
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	684	---
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	0/950 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach **Squamous Cell Papilloma**				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	2/40.02	1/43.53	2/43.98	3/20.05
POLY-3 PERCENT (g)	5%	2.3%	4.6%	15%
TERMINAL (d)	2/29 (7%)	0/33 (0%)	2/31 (7%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	692	729 (T)	492
HC TUMORS SAME ROUTE	15/250 (6%)			
HC TUMORS ALL ROUTES	24/950 (3%)			
STATISTICAL TESTS				
POLY 3	P=0.109	P=0.471N	P=0.660N	P=0.229
POLY 1.5	P=0.162	P=0.479N	P=0.671N	P=0.345
POLY 6	P=0.140	P=0.460N	P=0.645N	P=0.113
COCH-ARM / FISHERS	P=0.289	P=0.500N	P=0.691N	P=0.500
MAX-ISO-POLY-3	P=0.179	P=0.264N	P=0.462N	P=0.174
HISTCONT SAME RTE	P=0.464	P=1.000	P=1.000	P=0.322
HISTCONT ALL RTES	P=0.161	P=1.000	P=0.448	P=0.109
CURR VS HC SAME RTE	P=0.706			
CURR VS HC ALL RTES	P=0.484			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Testes **Adenoma**				
TUMOR RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	0/49 (0%)
POLY-3 RATE (b)	2/40.02	0/43.38	1/43.98	0/17.92
POLY-3 PERCENT (g)	5%	0%	2.3%	0%
TERMINAL (d)	2/29 (7%)	0/33 (0%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---
HC TUMORS SAME ROUTE	2/250 (1%)			
HC TUMORS ALL ROUTES	8/950 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.457N	P=0.219N	P=0.467N	P=0.437N
POLY 1.5	P=0.395N	P=0.225N	P=0.478N	P=0.337N
POLY 6	P=0.627N	P=0.213N	P=0.453N	P=0.583N
COCH-ARM / FISHERS	P=0.312N	P=0.247N	P=0.500N	P=0.253N
MAX-ISO-POLY-3	P=0.374N	P=0.075N	P=0.262N	P=0.259N
HISTCONT SAME RTE	P=0.639	P=1.000	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.666	P=1.000	P=0.451	P=1.000
CURR VS HC SAME RTE	P=0.051			
CURR VS HC ALL RTES	P=0.025*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Thyroid Gland: Follicular Cell Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	1/49 (2%)	2/50 (4%)	0/49 (0%)
POLY-3 RATE (b)	1/40.02	1/42.85	2/43.98	0/18.16
POLY-3 PERCENT (g)	2.5%	2.3%	4.6%	0%
TERMINAL (d)	1/29 (3%)	1/33 (3%)	2/31 (7%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---
HC TUMORS SAME ROUTE	1/249 (0%)			
HC TUMORS ALL ROUTES	7/944 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.597N	P=0.745N	P=0.533	P=0.638N
POLY 1.5	P=0.467N	P=0.751N	P=0.522	P=0.575N
POLY 6	P=0.512	P=0.738N	P=0.547	P=0.714N
COCH-ARM / FISHERS	P=0.333N	P=0.747	P=0.500	P=0.505N
MAX-ISO-POLY-3	P=0.541N	P=0.480N	P=0.316	P=0.323N
HISTCONT SAME RTE	P=0.396	P=0.324	P=0.045*	P=1.000
HISTCONT ALL RTES	P=0.245	P=0.388	P=0.008**	P=1.000
CURR VS HC SAME RTE	P=0.095			
CURR VS HC ALL RTES	P=0.312			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Thyroid Gland: Follicular Cell Carcinoma or Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	1/49 (2%)	2/50 (4%)	0/49 (0%)
POLY-3 RATE (b)	1/40.02	1/42.85	2/43.98	0/18.16
POLY-3 PERCENT (g)	2.5%	2.3%	4.6%	0%
TERMINAL (d)	1/29 (3%)	1/33 (3%)	2/31 (7%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---
HC TUMORS SAME ROUTE	1/249 (0%)			
HC TUMORS ALL ROUTES	8/944 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.597N	P=0.745N	P=0.533	P=0.638N
POLY 1.5	P=0.467N	P=0.751N	P=0.522	P=0.575N
POLY 6	P=0.512	P=0.738N	P=0.547	P=0.714N
COCH-ARM / FISHERS	P=0.333N	P=0.747	P=0.500	P=0.505N
MAX-ISO-POLY-3	P=0.541N	P=0.480N	P=0.316	P=0.323N
HISTCONT SAME RTE	P=0.396	P=0.324	P=0.045*	P=1.000
HISTCONT ALL RTES	P=0.331	P=0.450	P=0.022*	P=1.000
CURR VS HC SAME RTE	P=0.095			
CURR VS HC ALL RTES	P=0.377			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
All Organs **Histiocytic Sarcoma**				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/40.45	1/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	2.5%	2.3%	0%	0%
TERMINAL (d)	0/29 (0%)	1/33 (3%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	606	729 (T)	---	---
HC TUMORS SAME ROUTE	2/250 (1%)			
HC TUMORS ALL ROUTES	11/950 (1%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
All Organs				
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type				
TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	7/50 (14%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	5/40.21	7/43.38	1/44.78	0/18.16
POLY-3 PERCENT (g)	12.4%	16.1%	2.2%	0%
TERMINAL (d)	4/29 (14%)	7/33 (21%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	680	729 (T)	431	---
HC TUMORS SAME ROUTE	13/250 (5%)			
HC TUMORS ALL ROUTES	48/950 (5%)			
STATISTICAL TESTS				
POLY 3	P=0.020N*	P=0.433	P=0.078N	P=0.175N
POLY 1.5	P=0.015N*	P=0.418	P=0.085N	P=0.081N
POLY 6	P=0.017N*	P=0.449	P=0.070N	P=0.403N
COCH-ARM / FISHERS	P=0.007N**	P=0.380	P=0.102N	P=0.028N*
MAX-ISO-POLY-3	P=0.033N*	P=0.321	P=0.039N*	P=0.142N
HISTCONT SAME RTE	P=0.721	P=0.015*	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.692	P<0.001**	P=1.000	P=1.000
CURR VS HC SAME RTE	P=0.148			
CURR VS HC ALL RTES	P=0.094			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
All Organs **Benign Tumors**				
TUMOR RATES	#	#	#	#
OVERALL (a)	30/50 (60%)	39/50 (78%)	49/50 (98%)	41/50 (82%)
POLY-3 RATE (b)	30/44.19	39/48.01	49/49.59	41/43.55
POLY-3 PERCENT (g)	67.9%	81.2%	98.8%	94.1%
TERMINAL (d)	21/29 (72%)	29/33 (88%)	31/31 (100%)	0/0 (0%)
FIRST INCIDENCE	298	428	431	442
HC TUMORS SAME ROUTE	179/250 (72%)			
HC TUMORS ALL ROUTES	715/950 (75%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.094	P<0.001**	P<0.001**
POLY 1.5	P=0.003**	P=0.073	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.131	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.056	P=0.041*	P<0.001**	P=0.013*
MAX-ISO-POLY-3	P<0.001**	P=0.065	P<0.001**	P<0.001**
HISTCONT SAME RTE	P=0.017*	P=0.242	P=0.002**	P=0.005**
HISTCONT ALL RTES	P=0.008**	P=0.496	P<0.001**	P=0.010**
CURR VS HC SAME RTE	P=0.090			
CURR VS HC ALL RTES	P=0.042*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
All Organs **Malignant Tumors**				
TUMOR RATES	#	#	#	#
OVERALL (a)	27/50 (54%)	25/50 (50%)	37/50 (74%)	45/50 (90%)
POLY-3 RATE (b)	27/45.39	25/45.70	37/47.66	45/46.05
POLY-3 PERCENT (g)	59.5%	54.7%	77.6%	97.7%
TERMINAL (d)	14/29 (48%)	18/33 (55%)	25/31 (81%)	0/0 (0%)
FIRST INCIDENCE	491	540	431	451
HC TUMORS SAME ROUTE	144/250 (58%)			
HC TUMORS ALL ROUTES	593/950 (62%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.400N	P=0.041*	P<0.001**
POLY 1.5	P<0.001**	P=0.384N	P=0.042*	P<0.001**
POLY 6	P<0.001**	P=0.431N	P=0.039*	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.421N	P=0.030*	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.320N	P=0.027*	P<0.001**
HISTCONT SAME RTE	P=0.007**	P=1.000	P=0.051	P=0.006**
HISTCONT ALL RTES	P<0.001**	P=1.000	P=0.054	P<0.001**
CURR VS HC SAME RTE	P=0.873			
CURR VS HC ALL RTES	P=0.456			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
All Organs **Malignant and Benign Tumors**				
TUMOR RATES	#	#	#	#
OVERALL (a)	40/50 (80%)	46/50 (92%)	49/50 (98%)	48/50 (96%)
POLY-3 RATE (b)	40/47.62	46/49.01	49/49.59	48/48.00
POLY-3 PERCENT (g)	84%	93.9%	98.8%	100%
TERMINAL (d)	23/29 (79%)	32/33 (97%)	31/31 (100%)	0/0 (0%)
FIRST INCIDENCE	298	428	431	442
HC TUMORS SAME ROUTE	231/250 (92%)			
HC TUMORS ALL ROUTES	891/950 (94%)			
STATISTICAL TESTS				
POLY 3	P=0.005**	P=0.096	P=0.007**	P=0.003**
POLY 1.5	P=0.004**	P=0.101	P=0.007**	P=0.002**
POLY 6	P=0.008**	P=0.091	P=0.008**	P=0.005**
COCH-ARM / FISHERS	P=0.035*	P=0.074	P=0.004**	P=0.014*
MAX-ISO-POLY-3	P<0.001**	P=0.052	P=0.002**	P<0.001**
HISTCONT SAME RTE	P=0.068	P=1.000	P=0.138	P=0.085
HISTCONT ALL RTES	P=0.053	P=1.000	P=0.125	P=0.056
CURR VS HC SAME RTE	P=0.009**			
CURR VS HC ALL RTES	P<0.001**			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Adrenal Cortex Adenoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/49 (4%)	0/47 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	2/44.67	0/18.79
POLY-3 PERCENT (g)	0%	0%	4.5%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	2/36 (6%)	0/0 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
HC TUMORS SAME ROUTE	2/249 (1%)			
HC TUMORS ALL ROUTES	6/945 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.332	(e)	P=0.244	(e)
POLY 1.5	P=0.569	(e)	P=0.240	(e)
POLY 6	P=0.137	(e)	P=0.249	(e)
COCH-ARM / FISHERS	P=0.707N	(e)	P=0.242	(e)
MAX-ISO-POLY-3	P=0.438	(e)	P=0.084	(e)
HISTCONT SAME RTE	P=0.509	(e)	P=0.124	(e)
HISTCONT ALL RTES	P=0.257	(e)	P=0.011*	(e)
CURR VS HC SAME RTE	P=0.577			
CURR VS HC ALL RTES	P=0.613			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Harderian Gland Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	9/50 (18%)	1/50 (2%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	9/43.53	1/44.47	4/45.87	2/20.78
POLY-3 PERCENT (g)	20.7%	2.3%	8.7%	9.6%
TERMINAL (d)	8/33 (24%)	1/35 (3%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	656	729 (T)	677	542
HC TUMORS SAME ROUTE	16/250 (6%)			
HC TUMORS ALL ROUTES	60/950 (6%)			
STATISTICAL TESTS				
POLY 3	P=0.379N	P=0.007N**	P=0.095N	P=0.251N
POLY 1.5	P=0.266N	P=0.007N**	P=0.102N	P=0.093N
POLY 6	P=0.474N	P=0.007N**	P=0.086N	P=0.599N
COCH-ARM / FISHERS	P=0.130N	P=0.008N**	P=0.117N	P=0.026N*
MAX-ISO-POLY-3	P=0.210N	P=0.003N**	P=0.058N	P=0.220N
HISTCONT SAME RTE	P=0.506	P=1.000	P=0.451	P=1.000
HISTCONT ALL RTES	P=0.557	P=1.000	P=0.427	P=0.494
CURR VS HC SAME RTE	P=0.006**			
CURR VS HC ALL RTES	P<0.001**			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Harderian Gland Carcinoma or Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	10/50 (20%)	2/50 (4%)	5/50 (10%)	2/50 (4%)
POLY-3 RATE (b)	10/43.53	2/44.64	5/45.87	2/20.78
POLY-3 PERCENT (g)	23%	4.5%	10.9%	9.6%
TERMINAL (d)	9/33 (27%)	1/35 (3%)	4/37 (11%)	0/0 (0%)
FIRST INCIDENCE	656	684	677	542
HC TUMORS SAME ROUTE	18/250 (7%)			
HC TUMORS ALL ROUTES	79/950 (8%)			
STATISTICAL TESTS				
POLY 3	P=0.315N	P=0.011N*	P=0.105N	P=0.197N
POLY 1.5	P=0.192N	P=0.012N*	P=0.114N	P=0.061N
POLY 6	P=0.444N	P=0.011N*	P=0.095N	P=0.554N
COCH-ARM / FISHERS	P=0.075N	P=0.014N*	P=0.131N	P=0.014N*
MAX-ISO-POLY-3	P=0.226N	P=0.005N**	P=0.067N	P=0.182N
HISTCONT SAME RTE	P=0.497	P=1.000	P=0.325	P=1.000
HISTCONT ALL RTES	P=0.701	P=1.000	P=0.432	P=1.000
CURR VS HC SAME RTE	P=0.005**			
CURR VS HC ALL RTES	P=0.003**			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Intestine Small: Site Unspecified Carcinoma or Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	1/45.67	0/19.60
POLY-3 PERCENT (g)	0%	0%	2.2%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
HC TUMORS SAME ROUTE	3/250 (1%)			
HC TUMORS ALL ROUTES	10/950 (1%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Islets, Pancreatic Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	0/48 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.26	0/43.31	2/46.03	0/19.60
POLY-3 PERCENT (g)	2.3%	0%	4.4%	0%
TERMINAL (d)	1/33 (3%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	677	---
HC TUMORS SAME ROUTE	1/250 (0%)			
HC TUMORS ALL ROUTES	9/944 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.537	P=0.500N	P=0.522	P=0.638N
POLY 1.5	P=0.605N	P=0.501N	P=0.513	P=0.573N
POLY 6	P=0.355	P=0.497N	P=0.532	P=0.713N
COCH-ARM / FISHERS	P=0.467N	P=0.510N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.561N	P=0.161N	P=0.304	P=0.324N
HISTCONT SAME RTE	P=0.327	P=1.000	P=0.045*	P=1.000
HISTCONT ALL RTES	P=0.395	P=1.000	P=0.026*	P=1.000
CURR VS HC SAME RTE	P=0.096			
CURR VS HC ALL RTES	P=0.462			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Kidney: Renal Tubule Carcinoma or Adenoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.28	0/19.10
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	0/947 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Liver **Hepatoblastoma**				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	0/49 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/43.26	0/43.68	0/45.67	0/19.47
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	1/250 (0%)			
HC TUMORS ALL ROUTES	4/948 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Liver **Hepatocellular Adenoma**				
TUMOR RATES				
OVERALL (a)	5/50 (10%)	7/49 (14%)	32/50 (64%)	46/49 (94%)
POLY-3 RATE (b)	5/43.26	7/43.68	32/47.07	46/46.98
POLY-3 PERCENT (g)	11.6%	16%	68%	97.9%
TERMINAL (d)	5/33 (15%)	7/35 (20%)	26/37 (70%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	563	432
HC TUMORS SAME ROUTE	62/250 (25%)			
HC TUMORS ALL ROUTES	378/948 (40%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.385	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.383	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.391	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.365	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.276	P<0.001**	P<0.001**
HISTCONT SAME RTE	P<0.001**	P=1.000	P=0.004**	P<0.001**
HISTCONT ALL RTES	P<0.001**	P=1.000	P=0.039*	P<0.001**
CURR VS HC SAME RTE	P=0.054			
CURR VS HC ALL RTES	P<0.001**			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Liver **Hepatocellular Carcinoma**				
TUMOR RATES				
OVERALL (a)	4/50 (8%)	2/49 (4%)	6/50 (12%)	27/49 (55%)
POLY-3 RATE (b)	4/43.39	2/43.75	6/46.28	27/35.78
POLY-3 PERCENT (g)	9.2%	4.6%	13%	75.5%
TERMINAL (d)	3/33 (9%)	1/35 (3%)	4/37 (11%)	0/0 (0%)
FIRST INCIDENCE	696	712	598	432
HC TUMORS SAME ROUTE	26/250 (10%)			
HC TUMORS ALL ROUTES	152/948 (16%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.333N	P=0.411	P<0.001**
POLY 1.5	P<0.001**	P=0.335N	P=0.395	P<0.001**
POLY 6	P<0.001**	P=0.329N	P=0.430	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.349N	P=0.370	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.199N	P=0.294	P<0.001**
HISTCONT SAME RTE	P=0.004**	P=1.000	P=0.480	P=0.002**
HISTCONT ALL RTES	P<0.001**	P=1.000	P=1.000	P<0.001**
CURR VS HC SAME RTE	P=0.694			
CURR VS HC ALL RTES	P=0.167			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Hepatocellular Carcinoma or Hepatoblastoma				
TUMOR RATES				
OVERALL (a)	4/50 (8%)	2/49 (4%)	6/50 (12%)	27/49 (55%)
POLY-3 RATE (b)	4/43.39	2/43.75	6/46.28	27/35.78
POLY-3 PERCENT (g)	9.2%	4.6%	13%	75.5%
TERMINAL (d)	3/33 (9%)	1/35 (3%)	4/37 (11%)	0/0 (0%)
FIRST INCIDENCE	696	712	598	432
HC TUMORS SAME ROUTE	27/250 (11%)			
HC TUMORS ALL ROUTES	155/948 (16%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.333N	P=0.411	P<0.001**
POLY 1.5	P<0.001**	P=0.335N	P=0.395	P<0.001**
POLY 6	P<0.001**	P=0.329N	P=0.430	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.349N	P=0.370	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.199N	P=0.294	P<0.001**
HISTCONT SAME RTE	P=0.005**	P=1.000	P=1.000	P=0.002**
HISTCONT ALL RTES	P=0.002**	P=1.000	P=1.000	P<0.001**
CURR VS HC SAME RTE	P=0.655			
CURR VS HC ALL RTES	P=0.153			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Hepatocellular Carcinoma or Hepatocellular Adenoma				
TUMOR RATES				
OVERALL (a)	8/50 (16%)	8/49 (16%)	33/50 (66%)	47/49 (96%)
POLY-3 RATE (b)	8/43.39	8/43.75	33/47.52	47/47.57
POLY-3 PERCENT (g)	18.4%	18.3%	69.5%	98.8%
TERMINAL (d)	7/33 (21%)	7/35 (20%)	26/37 (70%)	0/0 (0%)
FIRST INCIDENCE	696	712	563	432
HC TUMORS SAME ROUTE	77/250 (31%)			
HC TUMORS ALL ROUTES	448/948 (47%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.602N	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.603N	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.596N	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.590	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.492N	P<0.001**	P<0.001**
HISTCONT SAME RTE	P<0.001**	P=1.000	P=0.006**	P<0.001**
HISTCONT ALL RTES	P=0.003**	P=1.000	P=0.099	P<0.001**
CURR VS HC SAME RTE	P=0.077			
CURR VS HC ALL RTES	P<0.001**			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma				
TUMOR RATES				
OVERALL (a)	8/50 (16%)	8/49 (16%)	33/50 (66%)	47/49 (96%)
POLY-3 RATE (b)	8/43.39	8/43.75	33/47.52	47/47.57
POLY-3 PERCENT (g)	18.4%	18.3%	69.5%	98.8%
TERMINAL (d)	7/33 (21%)	7/35 (20%)	26/37 (70%)	0/0 (0%)
FIRST INCIDENCE	696	712	563	432
HC TUMORS SAME ROUTE	77/250 (31%)			
HC TUMORS ALL ROUTES	448/948 (47%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.602N	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.603N	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.596N	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.590	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.492N	P<0.001**	P<0.001**
HISTCONT SAME RTE	P<0.001**	P=1.000	P=0.006**	P<0.001**
HISTCONT ALL RTES	P=0.003**	P=1.000	P=0.099	P<0.001**
CURR VS HC SAME RTE	P=0.077			
CURR VS HC ALL RTES	P<0.001**			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung **Alveolar/Bronchiolar Adenoma**				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	5/50 (10%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	1/43.26	5/44.69	3/45.87	0/19.60
POLY-3 PERCENT (g)	2.3%	11.2%	6.5%	0%
TERMINAL (d)	1/33 (3%)	3/35 (9%)	2/37 (5%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	687	677	---
HC TUMORS SAME ROUTE	10/250 (4%)			
HC TUMORS ALL ROUTES	54/949 (6%)			
STATISTICAL TESTS				
POLY 3	P=0.309N	P=0.108	P=0.327	P=0.638N
POLY 1.5	P=0.185N	P=0.108	P=0.319	P=0.573N
POLY 6	P=0.556N	P=0.110	P=0.337	P=0.713N
COCH-ARM / FISHERS	P=0.089N	P=0.102	P=0.309	P=0.500N
MAX-ISO-POLY-3	P=0.417N	P=0.051	P=0.176	P=0.324N
HISTCONT SAME RTE	P=0.636	P=0.075	P=0.391	P=1.000
HISTCONT ALL RTES	P=0.742	P=0.114	P=1.000	P=1.000
CURR VS HC SAME RTE	P=0.565			
CURR VS HC ALL RTES	P=0.290			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung **Alveolar/Bronchiolar Carcinoma**				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.26	1/44.47	1/45.67	0/19.60
POLY-3 PERCENT (g)	0%	2.3%	2.2%	0%
TERMINAL (d)	0/33 (0%)	1/35 (3%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---
HC TUMORS SAME ROUTE	6/250 (2%)			
HC TUMORS ALL ROUTES	38/949 (4%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung				
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	6/50 (12%)	4/50 (8%)	0/50 (0%)
POLY-3 RATE (b)	1/43.26	6/44.69	4/45.87	0/19.60
POLY-3 PERCENT (g)	2.3%	13.4%	8.7%	0%
TERMINAL (d)	1/33 (3%)	4/35 (11%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	687	677	---
HC TUMORS SAME ROUTE	16/250 (6%)			
HC TUMORS ALL ROUTES	90/949 (10%)			
STATISTICAL TESTS				
POLY 3	P=0.322N	P=0.061	P=0.197	P=0.638N
POLY 1.5	P=0.170N	P=0.060	P=0.190	P=0.573N
POLY 6	P=0.620N	P=0.062	P=0.206	P=0.713N
COCH-ARM / FISHERS	P=0.069N	P=0.056	P=0.181	P=0.500N
MAX-ISO-POLY-3	P=0.385N	P=0.028*	P=0.101	P=0.324N
HISTCONT SAME RTE	P=0.683	P=0.089	P=0.446	P=1.000
HISTCONT ALL RTES	P=1.000	P=0.329	P=1.000	P=1.000
CURR VS HC SAME RTE	P=0.262			
CURR VS HC ALL RTES	P=0.081			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Ovary				
Cystadenoma				
TUMOR RATES				
OVERALL (a)	2/48 (4%)	1/49 (2%)	3/50 (6%)	0/48 (0%)
POLY-3 RATE (b)	2/41.26	1/43.47	3/45.67	0/19.10
POLY-3 PERCENT (g)	4.9%	2.3%	6.6%	0%
TERMINAL (d)	2/31 (7%)	1/34 (3%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---
HC TUMORS SAME ROUTE	11/249 (4%)			
HC TUMORS ALL ROUTES	43/939 (5%)			
STATISTICAL TESTS				
POLY 3	P=0.540N	P=0.482N	P=0.546	P=0.429N
POLY 1.5	P=0.382N	P=0.483N	P=0.536	P=0.326N
POLY 6	P=0.459	P=0.479N	P=0.558	P=0.579N
COCH-ARM / FISHERS	P=0.233N	P=0.492N	P=0.520	P=0.247N
MAX-ISO-POLY-3	P=0.470N	P=0.269N	P=0.370	P=0.254N
HISTCONT SAME RTE	P=0.769	P=1.000	P=0.445	P=1.000
HISTCONT ALL RTES	P=1.000	P=1.000	P=0.452	P=1.000
CURR VS HC SAME RTE	P=0.994			
CURR VS HC ALL RTES	P=0.938			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pituitary Gland: Pars Distalis or Unspecified Site Adenoma				
TUMOR RATES				
OVERALL (a)	5/50 (10%)	5/47 (11%)	8/46 (17%)	0/45 (0%)
POLY-3 RATE (b)	5/43.26	5/43.13	8/43.42	0/17.90
POLY-3 PERCENT (g)	11.6%	11.6%	18.4%	0%
TERMINAL (d)	5/33 (15%)	5/35 (14%)	7/36 (19%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	563	---
HC TUMORS SAME ROUTE	10/247 (4%)			
HC TUMORS ALL ROUTES	72/933 (8%)			
STATISTICAL TESTS				
POLY 3	P=0.408N	P=0.629	P=0.277	P=0.196N
POLY 1.5	P=0.161N	P=0.619	P=0.255	P=0.095N
POLY 6	P=0.342	P=0.621N	P=0.304	P=0.419N
COCH-ARM / FISHERS	P=0.037N*	P=0.590	P=0.224	P=0.037N*
MAX-ISO-POLY-3	P=0.299N	P=0.497	P=0.191	P=0.158N
HISTCONT SAME RTE	P=0.351	P=0.065	P=0.011*	P=1.000
HISTCONT ALL RTES	P=0.576	P=0.347	P=0.031*	P=1.000
CURR VS HC SAME RTE	P=0.079			
CURR VS HC ALL RTES	P=0.524			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Pituitary Gland: Pars Intermedia Adenoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	2/47 (4%)	0/46 (0%)	0/45 (0%)
POLY-3 RATE (b)	0/43.26	2/43.19	0/42.88	0/17.90
POLY-3 PERCENT (g)	0%	4.6%	0%	0%
TERMINAL (d)	0/33 (0%)	1/35 (3%)	0/36 (0%)	0/0 (0%)
FIRST INCIDENCE	---	715	---	---
HC TUMORS SAME ROUTE	3/247 (1%)			
HC TUMORS ALL ROUTES	7/933 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.333N	P=0.237	(e)	(e)
POLY 1.5	P=0.346N	P=0.233	(e)	(e)
POLY 6	P=0.393N	P=0.241	(e)	(e)
COCH-ARM / FISHERS	P=0.341N	P=0.232	(e)	(e)
MAX-ISO-POLY-3	P=0.529N	P=0.079	(e)	(e)
HISTCONT SAME RTE	P=0.713	P=0.102	(e)	(e)
HISTCONT ALL RTES	P=0.639	P=0.014*	(e)	(e)
CURR VS HC SAME RTE	P=0.408			
CURR VS HC ALL RTES	P=0.608			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skeletal Muscle Rhabdomyosarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.60	2/44.92	2/46.49	0/19.60
POLY-3 PERCENT (g)	2.3%	4.5%	4.3%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	632	618	563	---
HC TUMORS SAME ROUTE	3/250 (1%)			
HC TUMORS ALL ROUTES	6/950 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.472N	P=0.510	P=0.522	P=0.639N
POLY 1.5	P=0.351N	P=0.509	P=0.514	P=0.574N
POLY 6	P=0.627	P=0.513	P=0.532	P=0.713N
COCH-ARM / FISHERS	P=0.232N	P=0.500	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.513N	P=0.292	P=0.305	P=0.326N
HISTCONT SAME RTE	P=0.607	P=0.235	P=0.243	P=1.000
HISTCONT ALL RTES	P=0.372	P=0.037*	P=0.039*	P=1.000
CURR VS HC SAME RTE	P=0.819			
CURR VS HC ALL RTES	P=0.265			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.73	2/44.47	0/45.67	0/19.60
POLY-3 PERCENT (g)	2.3%	4.5%	0%	0%
TERMINAL (d)	0/33 (0%)	2/35 (6%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	589	729 (T)	---	---
HC TUMORS SAME ROUTE	7/250 (3%)			
HC TUMORS ALL ROUTES	43/950 (5%)			
STATISTICAL TESTS				
POLY 3	P=0.213N	P=0.506	P=0.491N	P=0.639N
POLY 1.5	P=0.220N	P=0.507	P=0.494N	P=0.574N
POLY 6	P=0.235N	P=0.505	P=0.488N	P=0.714N
COCH-ARM / FISHERS	P=0.198N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.350N	P=0.287	P=0.158N	P=0.326N
HISTCONT SAME RTE	P=1.000	P=0.484	P=1.000	P=1.000
HISTCONT ALL RTES	(h)	(h)	(h)	(h)
CURR VS HC SAME RTE	P=0.786			
CURR VS HC ALL RTES	P=0.429			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.73	2/44.47	0/45.67	0/19.60
POLY-3 PERCENT (g)	2.3%	4.5%	0%	0%
TERMINAL (d)	0/33 (0%)	2/35 (6%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	589	729 (T)	---	---
HC TUMORS SAME ROUTE	7/250 (3%)			
HC TUMORS ALL ROUTES	43/950 (5%)			
STATISTICAL TESTS				
POLY 3	P=0.213N	P=0.506	P=0.491N	P=0.639N
POLY 1.5	P=0.220N	P=0.507	P=0.494N	P=0.574N
POLY 6	P=0.235N	P=0.505	P=0.488N	P=0.714N
COCH-ARM / FISHERS	P=0.198N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.350N	P=0.287	P=0.158N	P=0.326N
HISTCONT SAME RTE	P=1.000	P=0.484	P=1.000	P=1.000
HISTCONT ALL RTES	(h)	(h)	(h)	(h)
CURR VS HC SAME RTE	P=0.786			
CURR VS HC ALL RTES	P=0.429			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Skin				
Lipoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.67	0/19.60
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	0/950 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Mast Cell Tumor Benign				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.67	2/20.78
POLY-3 PERCENT (g)	0%	0%	0%	9.6%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	542
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	2/950 (0%)			
STATISTICAL TESTS				
POLY 3	P=0.025*	(e)	(e)	P=0.121
POLY 1.5	P=0.027*	(e)	(e)	P=0.169
POLY 6	P=0.117	(e)	(e)	P=0.080
COCH-ARM / FISHERS	P=0.041*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.035*	(e)	(e)	P=0.072
HISTCONT SAME RTE	P=0.086	(e)	(e)	P=0.061
HISTCONT ALL RTES	P=0.013*	(e)	(e)	P=0.002**
CURR VS HC SAME RTE	P=1.000			
CURR VS HC ALL RTES	P=0.547			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Stomach, Forestomach **Squamous Cell Papilloma**				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	3/50 (6%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/43.26	3/44.62	1/45.67	2/20.78
POLY-3 PERCENT (g)	0%	6.7%	2.2%	9.6%
TERMINAL (d)	0/33 (0%)	2/35 (6%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	---	690	729 (T)	542
HC TUMORS SAME ROUTE	7/250 (3%)			
HC TUMORS ALL ROUTES	15/950 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.279	P=0.124	P=0.511	P=0.121
POLY 1.5	P=0.354	P=0.124	P=0.507	P=0.169
POLY 6	P=0.372	P=0.125	P=0.516	P=0.080
COCH-ARM / FISHERS	P=0.482	P=0.121	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.195	P=0.042*	P=0.172	P=0.072
HISTCONT SAME RTE	P=0.298	P=0.169	P=1.000	P=0.217
HISTCONT ALL RTES	P=0.123	P=0.010**	P=1.000	P=0.059
CURR VS HC SAME RTE	P=0.249			
CURR VS HC ALL RTES	P=0.399			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Thyroid Gland: Follicular Cell Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	0/49 (0%)	0/48 (0%)	0/47 (0%)
POLY-3 RATE (b)	1/43.26	0/43.47	0/44.18	0/18.79
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	1/33 (3%)	0/34 (0%)	0/36 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	---	---
HC TUMORS SAME ROUTE	1/249 (0%)			
HC TUMORS ALL ROUTES	2/942 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
Thyroid Gland: Follicular Cell Carcinoma or Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	1/49 (2%)	0/48 (0%)	0/47 (0%)
POLY-3 RATE (b)	1/43.26	1/43.47	0/44.18	0/18.79
POLY-3 PERCENT (g)	2.3%	2.3%	0%	0%
TERMINAL (d)	1/33 (3%)	1/34 (3%)	0/36 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---
HC TUMORS SAME ROUTE	1/249 (0%)			
HC TUMORS ALL ROUTES	4/942 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Uterus **Polyp Stromal**				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	4/50 (8%)	0/50 (0%)
POLY-3 RATE (b)	0/43.26	2/44.47	4/45.69	0/19.60
POLY-3 PERCENT (g)	0%	4.5%	8.8%	0%
TERMINAL (d)	0/33 (0%)	2/35 (6%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	726	---
HC TUMORS SAME ROUTE	3/250 (1%)			
HC TUMORS ALL ROUTES	22/950 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.409	P=0.243	P=0.067	(e)
POLY 1.5	P=0.561N	P=0.243	P=0.065	(e)
POLY 6	P=0.134	P=0.244	P=0.071	(e)
COCH-ARM / FISHERS	P=0.346N	P=0.247	P=0.059	(e)
MAX-ISO-POLY-3	P=0.389	P=0.082	P=0.025*	(e)
HISTCONT SAME RTE	P=0.333	P=0.170	P=0.019*	(e)
HISTCONT ALL RTES	P=0.342	P=0.357	P=0.010**	(e)
CURR VS HC SAME RTE	P=0.499			
CURR VS HC ALL RTES	P=0.305			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
All Organs **Histiocytic Sarcoma**				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	3/50 (6%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.26	3/45.93	1/45.67	1/20.35
POLY-3 PERCENT (g)	2.3%	6.5%	2.2%	4.9%
TERMINAL (d)	1/33 (3%)	0/35 (0%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	522	729 (T)	459
HC TUMORS SAME ROUTE	6/250 (2%)			
HC TUMORS ALL ROUTES	23/950 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.537N	P=0.327	P=0.748N	P=0.575
POLY 1.5	P=0.491N	P=0.321	P=0.753N	P=0.673
POLY 6	P=0.581N	P=0.335	P=0.743N	P=0.431
COCH-ARM / FISHERS	P=0.396N	P=0.309	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.594	P=0.177	P=0.484N	P=0.351
HISTCONT SAME RTE	P=0.576	P=0.127	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.537	P=0.037*	P=1.000	P=1.000
CURR VS HC SAME RTE	P=0.917			
CURR VS HC ALL RTES	P=0.877			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
All Organs				
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type				
TUMOR RATES	#	#	#	#
OVERALL (a)	7/50 (14%)	6/50 (12%)	6/50 (12%)	1/50 (2%)
POLY-3 RATE (b)	7/44.29	6/45.28	6/45.67	1/20.29
POLY-3 PERCENT (g)	15.8%	13.3%	13.1%	4.9%
TERMINAL (d)	3/33 (9%)	5/35 (14%)	6/37 (16%)	0/0 (0%)
FIRST INCIDENCE	593	421	729 (T)	496
HC TUMORS SAME ROUTE	47/250 (19%)			
HC TUMORS ALL ROUTES	225/950 (24%)			
STATISTICAL TESTS				
POLY 3	P=0.232N	P=0.483N	P=0.476N	P=0.234N
POLY 1.5	P=0.103N	P=0.481N	P=0.483N	P=0.095N
POLY 6	P=0.460N	P=0.489N	P=0.472N	P=0.533N
COCH-ARM / FISHERS	P=0.026N*	P=0.500N	P=0.500N	P=0.030N*
MAX-ISO-POLY-3	P=0.372N	P=0.367N	P=0.361N	P=0.200N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)
CURR VS HC SAME RTE	P=0.502			
CURR VS HC ALL RTES	P=0.135			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
All Organs **Benign Tumors**				
TUMOR RATES	#	#	#	#
OVERALL (a)	24/50 (48%)	20/50 (40%)	38/50 (76%)	46/50 (92%)
POLY-3 RATE (b)	24/43.97	20/44.84	38/47.28	46/47.10
POLY-3 PERCENT (g)	54.6%	44.6%	80.4%	97.7%
TERMINAL (d)	22/33 (67%)	17/35 (49%)	30/37 (81%)	0/0 (0%)
FIRST INCIDENCE	601	687	563	432
HC TUMORS SAME ROUTE	114/250 (46%)			
HC TUMORS ALL ROUTES	531/950 (56%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.228N	P=0.005**	P<0.001**
POLY 1.5	P<0.001**	P=0.233N	P=0.004**	P<0.001**
POLY 6	P<0.001**	P=0.218N	P=0.008**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.273N	P=0.004**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.171N	P=0.003**	P<0.001**
HISTCONT SAME RTE	P=0.003**	P=1.000	P=0.007**	P=0.002**
HISTCONT ALL RTES	P=0.002**	P=1.000	P=0.030*	P<0.001**
CURR VS HC SAME RTE	P=0.518			
CURR VS HC ALL RTES	P=0.443			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
All Organs **Malignant Tumors**				
TUMOR RATES	#	#	#	#
OVERALL (a)	16/50 (32%)	15/50 (30%)	15/50 (30%)	31/50 (62%)
POLY-3 RATE (b)	16/45.24	15/47.43	15/47.09	31/38.52
POLY-3 PERCENT (g)	35.4%	31.6%	31.9%	80.5%
TERMINAL (d)	9/33 (27%)	7/35 (20%)	11/37 (30%)	0/0 (0%)
FIRST INCIDENCE	589	421	563	432
HC TUMORS SAME ROUTE	105/250 (42%)			
HC TUMORS ALL ROUTES	508/950 (54%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.436N	P=0.446N	P<0.001**
POLY 1.5	P<0.001**	P=0.447N	P=0.463N	P<0.001**
POLY 6	P<0.001**	P=0.427N	P=0.431N	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500N	P=0.500N	P=0.002**
MAX-ISO-POLY-3	P<0.001**	P=0.354N	P=0.362N	P<0.001**
HISTCONT SAME RTE	P=0.051	P=1.000	P=1.000	P=0.015*
HISTCONT ALL RTES	P=0.201	P=1.000	P=1.000	P=0.051
CURR VS HC SAME RTE	P=0.303			
CURR VS HC ALL RTES	P=0.007**			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

	Females			
DOSE	**0 MG/KG**	**3 MG/KG**	**30 MG/KG**	**100 MG/KG**
All Organs **Malignant and Benign Tumors**				
TUMOR RATES	#	#	#	#
OVERALL (a)	34/50 (68%)	30/50 (60%)	41/50 (82%)	49/50 (98%)
POLY-3 RATE (b)	34/45.68	30/47.74	41/47.73	49/49.13
POLY-3 PERCENT (g)	74.4%	62.8%	85.9%	99.7%
TERMINAL (d)	26/33 (79%)	20/35 (57%)	32/37 (87%)	0/0 (0%)
FIRST INCIDENCE	589	421	563	432
HC TUMORS SAME ROUTE	171/250 (68%)			
HC TUMORS ALL ROUTES	751/950 (79%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.156N	P=0.118	P<0.001**
POLY 1.5	P<0.001**	P=0.176N	P=0.100	P<0.001**
POLY 6	P<0.001**	P=0.138N	P=0.143	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.266N	P=0.083	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.112N	P=0.077	P<0.001**
HISTCONT SAME RTE	P=0.009**	P=1.000	P=0.046*	P=0.007**
HISTCONT ALL RTES	P=0.047*	P=1.000	P=0.373	P=0.018*
CURR VS HC SAME RTE	P=0.652			
CURR VS HC ALL RTES	P=0.191			

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(e)	Value of statistic cannot be computed.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
(g)	Poly-3 adjusted lifetime tumor incidence.
(h)	Historical Controls statistic is not calculated when the HC Poly-3 rate is higher than the Poly-3 rates for all dose groups.
(n)	No statistics are calculated if all dose groups have fewer than two tumors.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
N	Indicates a negative trend for all tests
	The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***